In­novent says next-gen GLP-1 drug from Lil­ly beats top di­a­betes med in Phase 3 Chi­na study

A next-gen­er­a­tion GLP-1 can­di­date from Eli Lil­ly has out­done an old­er Lil­ly drug in a Phase 3 tri­al in­volv­ing Chi­nese pa­tients with di­a­betes, Lil­ly part­ner In­novent an­nounced late Wednes­day.

The can­di­date, maz­du­tide, was “su­pe­ri­or com­pared with du­laglu­tide,” the ac­tive in­gre­di­ent in Trulic­i­ty, for glycemic con­trol af­ter 28 weeks of treat­ment, In­novent re­port­ed. With­out dis­clos­ing any da­ta, the com­pa­ny added that maz­du­tide al­so showed “mul­ti­ple car­diometa­bol­ic ben­e­fits,” in­clud­ing weight loss, blood lipid, blood pres­sure, serum uric acid and liv­er en­zymes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER